{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T18:13:36Z","timestamp":1698776016012},"reference-count":30,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":3385,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:p>The tolerability, pharmacodynamics, and pharmacokinetics of BIA 3\u2013202 (50 mg, 100 mg, and 200 mg twice daily and 200 mg thrice daily), a novel catechol\u2010O\u2010methyltransferase (COMT) inhibitor, were investigated in healthy volunteers. BIA 3\u2013202 was administered to four sequential groups of 8 healthy male subjects under a double\u2010blind, randomized, placebo\u2010controlled design. Within each group, 2 subjects were randomized to treatment with placebo. Treatment duration was 9 days: single dose on the first and last days and twice or thrice daily on days 3 to 8. BIA 3\u2013202 was well tolerated at all dose regimens tested. Median maximum plasma BIA 3\u2013202 concentrations were attained at 0.5 to 2.5 hours postdose. Thereafter, concentrations declined with a t<jats:sub>1\/2<\/jats:sub> of approximately 2 to 4 hours. The increase in the extent of systemic exposure, as measured by AUC<jats:sub>0\u2010\u03c4<\/jats:sub> was approximately proportional to the administered dose. Steady state of plasma BIA 3\u2013202 concentrations occurred by day 4 in all dose groups. Less than 1% of the total dose administered was excreted in urine up to 48 hours postdose. BIA 3\u2013202 markedly reduced soluble COMT (S\u2010COMT) activity in erythrocytes, with maximum inhibition occurring at 1 to 2 hours postdose; enzyme activity returned to baseline levels by approximately 8 hours. Inhibition of S\u2010COMT activity appeared to increase with increasing doses of BIA 3\u2013202 on both day 1 and day 9. In conclusion, BIA 3\u2013202 was well tolerated in all the oral multiple\u2010dose regimens tested. BIA 3\u2013202 was shown to inhibit S\u2010COMT activity in erythrocytes, and its pharmacokinetics appeared to be linear (i.e., dose independent and time invariant).<\/jats:p>","DOI":"10.1177\/0091270003258666","type":"journal-article","created":{"date-parts":[[2003,11,13]],"date-time":"2003-11-13T22:33:45Z","timestamp":1068762825000},"page":"1350-1360","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetic and Pharmacodynamic Profiles of BIA 3\u2013202, a Novel Catechol\u2010<i>O<\/i>\u2010Methyltransferase (COMT) Inhibitor, during Multiple\u2010Dose Administration to Healthy Subjects"],"prefix":"10.1002","volume":"43","author":[{"given":"Luis","family":"Almeida","sequence":"first","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares\u2010Da\u2010Silva","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198403000-00002"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5_Suppl_5.S3"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00032-1"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007772"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059060-00004"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200016010-00005"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200109000-00007"},{"key":"e_1_2_7_10_2","first-page":"1","volume-title":"Entacapone as an adjunctive treatment to levodopa in Parkinson's disease","author":"Shepherd J","year":"1999"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02879-0"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0109964"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01020-2"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000068730"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2003.920604.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200304040-00001"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1130030205"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15220.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)01063-X"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286159502900324"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835020-00001"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.3.250"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050068"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199502000-00006"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb05781.x"},{"key":"e_1_2_7_26_2","first-page":"593","article-title":"Catechol\u2010O\u2010methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors","volume":"51","author":"M\u00e4nnist\u00f6 PT","year":"1999","journal-title":"Pharmacol Rev"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.2000.2105"},{"key":"e_1_2_7_28_2","first-page":"812","article-title":"Studies on the tight\u2010binding nature of tolcapone inhibition of soluble and membrane\u2010bound rat brain catechol\u2010O\u2010methyltransferase","volume":"282","author":"Borges N","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00173538"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90673-4"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199880"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270003258666","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270003258666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:29:34Z","timestamp":1697228974000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270003258666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1177\/0091270003258666"],"URL":"https:\/\/doi.org\/10.1177\/0091270003258666","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}